Term
|
Definition
| increase the contractile force of cardiac myocytes |
|
|
Term
|
Definition
| intraventricular blood volume |
|
|
Term
|
Definition
| resistance against left ventricle ejection |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Ca stimulates this receptor on SR |
|
Definition
|
|
Term
| Cacliuum binds to which troponin |
|
Definition
| Troponin C: release inhibitory troponin I |
|
|
Term
|
Definition
|
|
Term
|
Definition
| increased force of contraction due to increased end diastolic volume of the left ventricle |
|
|
Term
|
Definition
| increased stretch releases more Ca from SR and allows for more actin/myosin binding sites |
|
|
Term
| 2 types of pumps in cardiac muscle |
|
Definition
| Na/K ATPase, and NA/Ca Exchanger |
|
|
Term
|
Definition
| SERCA once phospholamban is phosphorylated |
|
|
Term
| Phosphorylates phospholamban |
|
Definition
|
|
Term
|
Definition
| increased heart rate in dose format |
|
|
Term
| Positive Lusitropic effect |
|
Definition
| enhanced rate and extent of disastolic relaxation |
|
|
Term
|
Definition
| Lusitropic effect is very important to maintain output with increased HR |
|
|
Term
|
Definition
| dilates vascular smooth muscle, increased gluconeogenesis, glycogenolysis |
|
|
Term
|
Definition
| increase chronotrophy and inotropy, increased AV node velocity, increased renin secretion |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
Vascular smooth muscle contraction
GU SM contraction
GI SM RELAXATION
Heart: increased Rate and Inotrophy |
|
|
Term
|
Definition
| decrease insulin, block platelet aggreg, decrease NE release, Vascular smooth muscle contraction |
|
|
Term
|
Definition
| decreased systemic resistance, and afterload |
|
|
Term
|
Definition
| increased vascular reisistance and afterload |
|
|
Term
|
Definition
| inhibits Na/K ATPase channel |
|
|
Term
|
Definition
| increases intracellular Na and leads to decreased calcium efflux and thus SR can pick up more Ca+ |
|
|
Term
|
Definition
| decreased automaticity of AV node, prologned refractory period of AV node, inhibits sympathetic outflow and increased parasympathetic tone |
|
|
Term
|
Definition
|
|
Term
| Digoxin can be effected by what ion |
|
Definition
| Hypokalemia- increases digoxen binding in heart muscle |
|
|
Term
| Digoxin can be effected by what ion |
|
Definition
| Hypokalemia- increases digoxen binding in heart muscle |
|
|
Term
|
Definition
| Hyperkalemia to promote dephosphorylation of proteins |
|
|
Term
| Digoxen plus Beta blockers |
|
Definition
|
|
Term
| Beta blockers/Ca blockers effects on digoxen |
|
Definition
| block the inotrophic effects |
|
|
Term
| K wasting diuretics (furosemide) + digoxen |
|
Definition
| decrease plasma potassium and can lead to increased affinity of digoxen with NA/K ATPase channels |
|
|
Term
| Life threatening Digoxen overdose |
|
Definition
|
|
Term
|
Definition
| Systolic heart faiure, Supraventricular arrythmias (afib, a flutter, paroxysmal atrial tachy) |
|
|
Term
|
Definition
| Systolic heart faiure, Supraventricular arrythmias (afib, a flutter, paroxysmal atrial tachy) |
|
|
Term
|
Definition
| with kidney failure (due to liver metabolism) |
|
|
Term
|
Definition
| arrhythmias, AV block, PVC, agitation, blurred vision with yellow green halo |
|
|
Term
|
Definition
| Never with ventricular fib. or tachy |
|
|
Term
|
Definition
| life threatening digitalis toxicity |
|
|
Term
|
Definition
| Heart failure, anaphylaxis |
|
|
Term
|
Definition
| overall cardiostimulatory effect |
|
|
Term
|
Definition
| vasodilatory effect thru D1 in renal and mesenteric vascular beds |
|
|
Term
| Dopamine intermediate infusion |
|
Definition
| vasodilation via stimulation of B2 receptors and activates b1 receptors increasing rate and strength of contraction |
|
|
Term
|
Definition
| activates A1 receptor leading to vasoconstriction and increased afterload |
|
|
Term
|
Definition
|
|
Term
|
Definition
| Bradycardia, asthma, wideening of QRS, arrhythmias |
|
|
Term
|
Definition
| pheochromocytoma, v fib, uncorrected tachy arrhythmias |
|
|
Term
|
Definition
| decrease metabolism and result in tachycardia and arrhythmia |
|
|
Term
|
Definition
|
|
Term
|
Definition
| modest peripheral vasodilation via b2 receptor |
|
|
Term
|
Definition
| treates cardiac decompensation due to cardiogenic shock |
|
|
Term
|
Definition
| less frequent arrhytmias than dopamine |
|
|
Term
|
Definition
| Bronchospasm, anaphylactic shock, cardiac resuscitation, nasal congestion |
|
|
Term
|
Definition
| open angle glaucoma, prolongs local anethetic use |
|
|
Term
|
Definition
| non selective a1, a2, b1, b2 agonist |
|
|
Term
|
Definition
|
|
Term
|
Definition
| a1 vasoconstriction and increased afterload |
|
|
Term
|
Definition
|
|
Term
|
Definition
| nonselective b1, a1 and a2 agonist |
|
|
Term
|
Definition
| used for acute hemodynamic support due to shock in the absence of heart disease |
|
|
Term
|
Definition
| arrhythmias, cerebral hemorrhage, hypertension, headache, tachycardia, nervousness |
|
|
Term
|
Definition
|
|
Term
|
Definition
| emergency arrhythmias, atropine resistant arr, heart block, broncospasm |
|
|
Term
|
Definition
| do not use with angina or digitalis intoxication |
|
|
Term
|
Definition
| PDE inhibitor leading to increased cAMP and increased Ca intracellularly |
|
|
Term
|
Definition
| PDE inhibitor leading to increased cAMP and increased Ca intracellularly |
|
|
Term
|
Definition
| PDE inhibitor leading to increased cAMP and increased Ca intracellularly |
|
|
Term
|
Definition
| decrease preload and decrease after load |
|
|
Term
|
Definition
|
|
Term
|
Definition
| reversible neutropenia and agranulocytosis |
|
|
Term
|
Definition
| enhances troponin c to calcium sensitivity and induces periperial vasodilation |
|
|
Term
|
Definition
|
|
